期刊文献+

注射用雷替曲塞在输液中的稳定性考察 被引量:2

Evaluation on stability of raltitrexed for injection in infusions
原文传递
导出
摘要 目的:考察注射用雷替曲塞用0.9%氯化钠注射液或5%葡萄糖注射液溶解稀释后输液的稳定性。方法:模拟临床实际情况,分别考察雷替曲塞输液在不同温度下(4℃冰箱内、25℃室内不避光和37℃室内不避光)24 h内的外观、不溶性微粒、pH值和含量的变化。结果:雷替曲塞输液在不同温度下24 h内的外观和pH值均无明显改变,不溶性微粒符合药典相关规定,雷替曲塞相对初始含量的变化范围在93.9%~100.7%之间。结论:在临床常见情况下,雷替曲塞输液在24 h内的稳定性良好,不必现配现用。 OBJECTIVE To investigate the stability of raltitrexed for injection in infusions after dissolved and diluted with0.9% sodium chloride or 5% glucose injection.METHODS Under simulated clinical practical conditions,the appearance,particulate matter pH values and contents of raltitrexed infusion were evaluated within24 h under different temperatures(4 ℃in a refrigerator,25℃ under indoor light and 37℃ under indoor light).RESULTS There were no significount changes in the appearance and pH value of the infusion within 24 under different temperatures.The particulate matter met the relevant reguirements of the pharmacopoeia.The relative initial contents of raltitrexed varied between 93.9% and 100.7%.CONCLUSION Raltitrexed for injection in infusions is stable under clinical common conditions within 24 h.
出处 《中国医院药学杂志》 CAS 北大核心 2017年第18期1847-1849,共3页 Chinese Journal of Hospital Pharmacy
基金 常州市卫生计生委重大科技项目(编号:ZD201611)
关键词 雷替曲塞 稳定性 输液 raltitrexed stability infusion
  • 相关文献

参考文献9

二级参考文献69

  • 1薛苏阳,李佳睿,张文雷,王鑫森,郑瑞鹏,王雪,王大伟.应用雷替曲塞行介入治疗结直肠癌肝转移的疗效[J].中国老年学杂志,2014,34(10):2887-2888. 被引量:10
  • 2岳顺,张大红,周磊磊.雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效[J].肿瘤防治研究,2014,41(2):160-162. 被引量:21
  • 3虞心红,毛庆华,张卫东,陈振杰,孙乐盈.胸苷酸合成酶抑制剂雷替曲塞的合成[J].华东理工大学学报(自然科学版),2005,31(2):184-188. 被引量:9
  • 4雷替曲塞反注射用无菌粉末[J].中国医药技术与市场,2006,6(1):48-49. 被引量:1
  • 5叶红,潘玲丽.头孢类抗菌素在输液中的稳定性[J].中国药师,2006,9(11):1069-1071. 被引量:9
  • 6Glimelius B, Hoffman K, Graf W, et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group [J]. Cancer, 1994, 73(3) :556 -562.
  • 7Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5FU + LV) in patients with advanced colorectal cancer (ACC) : resuhs of a randomized, multicenter, North American trial [ C]. Denver:Proc Am Soc, 1997 :a801.
  • 8Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group [ J ]. J Clin Oncol, 1998, 16(9) : 2943 -2952.
  • 9Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing Tomudex ( raltitrexed ) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. 'Tomudex' Colorectal Cancer Study Group [J]. Ann Oncol, 1996, 7(9) : 961 - 965.
  • 10Maughan T, James R, Kerr D, et al. Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimen in the palliative chemotherapy of advanced colorectal cancer ( CRC ) : final results of MRC CRO6 [J]. Ann Oncol, 2000, 11(Suppl4): a1850.

共引文献184

同被引文献28

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部